Hengrui Pharma(SH:600276) Xin Hua Ri Bao·2025-06-10 20:51Core Viewpoint - The National Medical Products Administration has approved 11 innovative drugs for market launch, with 5 of them coming from Jiangsu province, indicating a strong focus on promoting local pharmaceutical innovation [1][2]. Group 1: Approved Innovative Drugs - Jiangsu province has received approval for 7 domestic Class 1 innovative drugs this year, with the latest batch including 5 drugs from Suzhou (3), Lianyungang (1), and Taizhou (1) [1]. - The approved drugs include: - Injection of Rukang Qumai (瑞康曲妥珠单抗) for treating HER2 mutated non-small cell lung cancer (NSCLC) patients [1]. - Hydrochloride of Jikaxitini tablets for patients with primary myelofibrosis and related conditions [1]. - Injection of Zenidatuzumab for HER2 high-expressing cholangiocarcinoma patients who have received prior systemic therapy [1]. - Malic acid of Famitinib capsules for recurrent or metastatic cervical cancer patients who failed platinum-based chemotherapy [2]. - Injection of Agrestin α for adult patients undergoing chemotherapy that may cause febrile neutropenia [2]. Group 2: Regulatory and Supportive Measures - The Jiangsu Provincial Drug Administration is implementing comprehensive reforms to enhance the pharmaceutical and medical device regulatory environment, aiming to create a high-quality development policy landscape [2][3]. - The administration has established a service mechanism to support innovative drug development, focusing on personalized guidance throughout the clinical trial and approval processes [2][3]. - Ongoing efforts include building a competitive strategic emerging industry cluster and promoting open innovation across the entire biopharmaceutical industry chain [3].